3 results
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…
Primary objective:• To assess the mass balance of nanatinostat (ie, evaluate clearance mechanisms of nanatinostat and drug-related metabolites) following a single oral dose of [14C]-nanatinostat in patients with advanced cancer.Secondary objectives…
Primary Objective:To establish the maximum tolerated healthy liver-absorbed dose of 166Ho-microspheres in patients with HCC who receive RL as a bridge to resection.Secondary Objective(s): 1) To establish dose-response relationships between:a. The…